Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules

Cybin Inc. (NYSE: CYBN) a company developing novel psychedelic compounds for therapeutic use, has received a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (DEA).

The license is a requirement for any investigators intending to study, produce or analyze Schedule I substances. Before obtaining the license, Cybin conducted much of its R&D work through globally-licensed …

Full story available on Benzinga.com

More Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules